See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $23.9B | 12.1x | -93.9x | |
| $17.3B | 4.0x | 15.1x | |
| $11.8B | 3.9x | 27.7x | |
| $8.0B | 9.2x | -34.9x | |
| $3.7B | 9.8x | 79.8x | |
| $2.5B | 2.8x | 15.3x | |
| $2.5B | 4.9x | 45.9x | |
| $2.3B | 4.8x | 21.2x | |
| $1.9B | n/a | n/a | |
| $1.5B | 4.1x | -13.4x | |
| $1.3B | 2.1x | -10.6x | |
| $1.2B | 1.9x | 18.1x | |
| $931M | 110.5x | -5.2x | |
| $887M | 6.4x | -1.3x | |
| $795M | 1.0x | 25.6x | |
| $769M | 4.9x | -4.7x | |
| $725M | 2.3x | 12.9x | |
| $692M | 10.4x | n/a | |
| $629M | 1.8x | 21.5x | |
| $562M | 76.7x | -5.5x | |
| $448M | 122.4x | n/a | |
| $442M | 1.4x | 12.2x | |
| $403M | 1.3x | -29.0x | |
| $387M | 5.1x | -5.1x | |
| $289M | n/a | n/a | |
| $263M | n/a | n/a | |
| $261M | 63.3x | n/a | |
| $259M | n/a | -47.9x | |
| $237M | 5.4x | -2.1x | |
| $218M | 4.5x | -3.0x | |
| $217M | n/a | n/a | |
| $184M | 2.6x | -4.5x | |
| $178M | n/a | -1.1x | |
| $171M | n/a | -1.7x | |
| $164M | n/a | -1.5x | |
| $156M | n/a | -1.7x | |
| $154M | 2.3x | -3.7x | |
| $149M | 54.0x | -7.5x | |
| $117M | 1.6x | n/a | |
| $112M | 4.7x | -0.6x | |
| $111M | 7.9x | -0.6x | |
| $87.8M | 4.5x | n/a | |
| $70.4M | 15.0x | -0.6x | |
| $53.9M | 1.2x | n/a | |
| $25.1M | 1.0x | -0.5x | |
| $18.5M | 8.4x | -0.4x | |
| $12.9M | n/a | n/a | |
| $11.6M | 0.4x | -0.1x | |
| $7.9M | n/a | n/a | |
| $6.7M | 0.7x | -0.0x | |
| $4.7M | n/a | -0.1x | |
| $0.9M | n/a | n/a | |
| -$8.9M | n/a | n/a | |
| -$15.7M | -1.2x | n/a | |
| -$61.3M | -0.8x | n/a | |
| -$81.7M | -2.2x | 0.9x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine